LNPs have emerged as a key and increasingly popular system for drug delivery, particularly since they received FDA approval to intravenously deliver liver small interfering RNAs (siRNAs) to inhibit the synthesis of transthyretin in patients with hereditary transthyretin-mediated amyloidosis (Akinc et al., 2019) and to intramuscularly administer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines (Baden et al., 2021; Polack et al., 2020; Paunovska et al., 2022). Here, TTR is linked to amyloidosis.